Biomay

Biomay is committed to becoming a global leader in the research, discovery, and development of disease-modifying allergy therapies. Biomay AG's products will significantly improve patients' quality of life by treating diseases over the long term. Biomay AG discovers and develops recombinant allergy vaccines with superior efficacy and safety, which are innovative vaccines based on cutting-edge science in immunotherapy and prevention generated through close collaboration with academic partners.